Abumweis Suhad, Alzyoud Lara, Alqadi Sarah
College of Pharmacy, Al Ain University, Abu Dhabi 64141, United Arab Emirates.
Department of Clinical Nutrition and Dietetics, Faculty of Applied Medical Sciences, The Hashemite University, Zarqa 13133, Jordan.
Prev Nutr Food Sci. 2023 Dec 31;28(4):377-385. doi: 10.3746/pnf.2023.28.4.377.
Plant sterols/stanols are effective cholesterol-lowering agents. However, it is unclear whether the apolipoprotein E () genetic variants influence it. We investigated whether genetic variants modulate the responses of blood lipids to dietary intervention plant sterols/stanols in adults and if the intervention dose and duration, as well as the age and status of participants, influence this effect. Randomized clinical trials were identified by searching databases in the Cochrane Library. Random-effect models were used to estimate the pooled effect size of each outcome of interest total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein cholesterol, and triglycerides. Meta-regression and subgroup analysis were used to investigate the effects of potential modifiers on the outcomes of interest. Eleven articles were selected from 3,248 retrieved abstracts. Plant sterol/stanol intervention was associated with a more significant reduction in LDL levels in the E3 group [-0.251 mmol/L; 95% confidence interval (95% CI), -0.488 to -0.015] compared with both the E4 and E2 groups. In E4 carriers, the plant sterol/stanol intervention dose and duration resulted in a larger decrease in LDL levels (-0.088027 mmol/L; 95% CI, -0.154690 to -0.021364). In conclusion, genetic variants affected the response of blood LDL levels to supplementation with plant sterols/stanols, as individuals with E3 variant showed significantly decreased LDL levels compared with the other genotypes. However, future studies recruiting participants according to their genetic variants are needed to confirm our conclusion.
植物甾醇/甾烷醇是有效的降胆固醇药物。然而,载脂蛋白E()基因变异是否会对其产生影响尚不清楚。我们研究了基因变异是否会调节成年人血脂对膳食干预植物甾醇/甾烷醇的反应,以及干预剂量和持续时间,以及参与者的年龄和状况是否会影响这种效果。通过检索Cochrane图书馆的数据库来确定随机临床试验。采用随机效应模型来估计每个感兴趣结局(总胆固醇、低密度脂蛋白(LDL)胆固醇、高密度脂蛋白胆固醇和甘油三酯)的合并效应大小。采用Meta回归和亚组分析来研究潜在调节因素对感兴趣结局的影响。从3248篇检索到的摘要中筛选出11篇文章。与E4组和E2组相比,植物甾醇/甾烷醇干预在E3组中使LDL水平降低更为显著[-0.251 mmol/L;95%置信区间(95%CI),-0.488至-0.015]。在E4携带者中,植物甾醇/甾烷醇的干预剂量和持续时间导致LDL水平下降幅度更大(-0.088027 mmol/L;95%CI,-0.154690至-0.021364)。总之,基因变异影响了血液LDL水平对补充植物甾醇/甾烷醇的反应,因为与其他基因型相比,携带E3变异的个体LDL水平显著降低。然而,未来需要根据基因变异招募参与者的研究来证实我们的结论。